Advertisement

Drugs in R & D

, Volume 4, Issue 5, pp 312–319 | Cite as

Influenza Virus Vaccine Live Intranasal — MedImmune Vaccines

CAIV-T, Influenza Vaccine Live Intranasal
Adis R&D Profile

Keywords

Influenza Placebo Recipient Influenza Virus Vaccine Inactivate Influenza Vaccine Tissue Culture Infectious Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    MedImmune Inc. FDA Approves FluMist™ First Nasal Mist Influenza Vaccine Licensed in the US. Media Release: 17 Jun 2003. Available from URL: http://www.medimmune.com
  2. 2.
    Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. Journal of the American Medical Association 282: 137–144, 14 Jul 1999PubMedCrossRefGoogle Scholar
  3. 3.
    Jackson LA, Holmes SJ, Mendelman PM. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, admin-istered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17: 1905–1909, 9 Apr 1999PubMedCrossRefGoogle Scholar
  4. 4.
    Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, coldadapted influenza vaccine in preschool-aged children. Pediatrics 110: 662–672, Oct 2002PubMedCrossRefGoogle Scholar
  5. 5.
    Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18: 899–906, 10 Dec 1999PubMedCrossRefGoogle Scholar
  6. 6.
    Longini Jr IM, Halloran ME, Nizam A, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 18: 1902–1909, 17 Mar 2000PubMedCrossRefGoogle Scholar
  7. 7.
    Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, in-tranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. Journal of Pediatrics 136: 168–175, Feb 2000PubMedCrossRefGoogle Scholar
  8. 8.
    Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal in-fluenzavirus vaccine in children. New England Journal of Medicine 338: 1405–1412, 14 May 1998PubMedCrossRefGoogle Scholar
  9. 9.
    Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. Journal of Infectious Diseases 181: 1133–1137, Mar 2000PubMedCrossRefGoogle Scholar
  10. 10.
    Zangwill KM, Droge J, Mendelman P, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatric Infectious Disease Journal 20: 740–746, Aug 2001PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Personalised recommendations